Breaking News, Collaborations & Alliances

Goodwin Biotech, Alethia Biotherapeutics In Cancer Pact

Goodwin Biotechnology, Inc. (GBI) and Alethia Biotherapeutics, Inc. have entered a collaboration for the development of a mammalian cell line-based IgG monoclonal antibody project for the treatment of cancer.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Goodwin Biotechnology, Inc. (GBI) and Alethia Biotherapeutics, Inc. have entered a collaboration for the development of a mammalian cell line-based IgG monoclonal antibody project for the treatment of cancer. Terms of the agreement were not disclosed. “AB-16B5 is a humanized IgG2 monoclonal antibody which targets secreted clusterin for the inhibition of cancer-associated epithelial-to-mesenchymal transition (EMT), and it has shown positive pre-clinical results in representative cancer mod...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters